Annual EBIT
-$52.24 M
+$38.81 M+42.63%
December 31, 2022
Summary
- As of February 10, 2025, JNCE annual earnings before interest & taxes is -$52.24 million, with the most recent change of +$38.81 million (+42.63%) on December 31, 2022.
- During the last 3 years, JNCE annual EBIT has fallen by -$105.06 million (-198.91%).
Performance
JNCE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBIT
$50.34 M
+$81.74 M+260.29%
December 31, 2022
Summary
- As of February 10, 2025, JNCE quarterly earnings before interest & taxes is $50.34 million, with the most recent change of +$81.74 million (+260.29%) on December 31, 2022.
- Over the past year, JNCE quarterly EBIT has increased by +$80.62 million (+266.23%).
Performance
JNCE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBIT
-$52.24 M
+$80.62 M+60.68%
December 31, 2022
Summary
- As of February 10, 2025, JNCE TTM earnings before interest & taxes is -$52.24 million, with the most recent change of +$80.62 million (+60.68%) on December 31, 2022.
- Over the past year, JNCE TTM EBIT has increased by +$38.81 million (+42.63%).
Performance
JNCE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
JNCE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.6% | +266.2% | +42.6% |
| 3 y3 years | -198.9% | +313.9% | -198.9% |
| 5 y5 years | -171.9% | +535.8% | -198.9% |
JNCE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +74.3% | at high | -174.4% | at high | +154.3% |
| 5 y | 5-year | -198.9% | +74.3% | at high | -174.4% | -198.9% | +154.3% |
| alltime | all time | -198.9% | +74.3% | -48.6% | -174.4% | -171.4% | +154.3% |
Jounce Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$52.24 M(-42.6%) | $50.34 M(-260.3%) | -$52.24 M(-60.7%) |
| Sep 2022 | - | -$31.41 M(-6.8%) | -$132.86 M(+1.0%) |
| Jun 2022 | - | -$33.71 M(-10.0%) | -$131.60 M(+29.1%) |
| Mar 2022 | - | -$37.46 M(+23.7%) | -$101.94 M(+11.9%) |
| Dec 2021 | -$91.06 M(+101.8%) | -$30.28 M(+0.5%) | -$91.06 M(+259.2%) |
| Sep 2021 | - | -$30.14 M(+644.4%) | -$25.35 M(+24.8%) |
| Jun 2021 | - | -$4.05 M(-84.8%) | -$20.32 M(-54.4%) |
| Mar 2021 | - | -$26.58 M(-175.0%) | -$44.52 M(-1.3%) |
| Dec 2020 | -$45.12 M(-185.4%) | $35.42 M(-241.1%) | -$45.12 M(-56.6%) |
| Sep 2020 | - | -$25.10 M(-11.1%) | -$104.07 M(-651.2%) |
| Jun 2020 | - | -$28.25 M(+3.9%) | $18.88 M(-51.7%) |
| Mar 2020 | - | -$27.18 M(+15.5%) | $39.12 M(-25.9%) |
| Dec 2019 | $52.82 M | -$23.53 M(-124.0%) | $52.82 M(-27.8%) |
| Sep 2019 | - | $97.85 M(-1322.0%) | $73.20 M(-319.3%) |
| Jun 2019 | - | -$8.01 M(-40.6%) | -$33.38 M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$13.49 M(+329.0%) | -$31.02 M(-0.9%) |
| Dec 2018 | -$31.29 M(+62.9%) | -$3.15 M(-64.0%) | -$31.29 M(-21.2%) |
| Sep 2018 | - | -$8.74 M(+55.0%) | -$39.70 M(+12.3%) |
| Jun 2018 | - | -$5.64 M(-59.0%) | -$35.35 M(+8.0%) |
| Mar 2018 | - | -$13.77 M(+19.2%) | -$32.74 M(+70.4%) |
| Dec 2017 | -$19.21 M(+32.8%) | -$11.55 M(+163.3%) | -$19.21 M(+616.7%) |
| Sep 2017 | - | -$4.39 M(+44.9%) | -$2.68 M(-148.6%) |
| Jun 2017 | - | -$3.03 M(+1125.9%) | $5.52 M(-244.9%) |
| Mar 2017 | - | -$247.00 K(-105.0%) | -$3.81 M(-73.6%) |
| Dec 2016 | -$14.47 M(-52.4%) | $4.98 M(+30.6%) | -$14.47 M(-51.1%) |
| Sep 2016 | - | $3.81 M(-130.9%) | -$29.59 M(-11.4%) |
| Jun 2016 | - | -$12.36 M(+13.4%) | -$33.40 M(+58.8%) |
| Mar 2016 | - | -$10.90 M(+7.5%) | -$21.04 M(+107.5%) |
| Dec 2015 | -$30.40 M(+87.5%) | -$10.14 M | -$10.14 M |
| Dec 2014 | -$16.21 M | - | - |
FAQ
- What is Jounce Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Jounce Therapeutics?
- What is Jounce Therapeutics annual EBIT year-on-year change?
- What is Jounce Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Jounce Therapeutics?
- What is Jounce Therapeutics quarterly EBIT year-on-year change?
- What is Jounce Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Jounce Therapeutics?
- What is Jounce Therapeutics TTM EBIT year-on-year change?
What is Jounce Therapeutics annual earnings before interest & taxes?
The current annual EBIT of JNCE is -$52.24 M
What is the all time high annual EBIT for Jounce Therapeutics?
Jounce Therapeutics all-time high annual earnings before interest & taxes is $52.82 M
What is Jounce Therapeutics annual EBIT year-on-year change?
Over the past year, JNCE annual earnings before interest & taxes has changed by +$38.81 M (+42.63%)
What is Jounce Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of JNCE is $50.34 M
What is the all time high quarterly EBIT for Jounce Therapeutics?
Jounce Therapeutics all-time high quarterly earnings before interest & taxes is $97.85 M
What is Jounce Therapeutics quarterly EBIT year-on-year change?
Over the past year, JNCE quarterly earnings before interest & taxes has changed by +$80.62 M (+266.23%)
What is Jounce Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of JNCE is -$52.24 M
What is the all time high TTM EBIT for Jounce Therapeutics?
Jounce Therapeutics all-time high TTM earnings before interest & taxes is $73.20 M
What is Jounce Therapeutics TTM EBIT year-on-year change?
Over the past year, JNCE TTM earnings before interest & taxes has changed by +$38.81 M (+42.63%)